![]() | |
Clinical data | |
---|---|
Trade names | Tractocile, Antocin, others[1] |
AHFS/Drugs.com | UK Drug Information |
License data | |
Routes of administration | Intravenous |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.234.128 |
Chemical and physical data | |
Formula | C43H67N11O12S2 |
Molar mass | 994.19 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
Atosiban, sold under the brand name Tractocile among others, is an inhibitor of the hormones oxytocin and vasopressin. It is used as an intravenous medication as a labour repressant (tocolytic) to halt premature labor. It was developed by Ferring Pharmaceuticals in Sweden and first reported in the literature in 1985.[5] Originally marketed by Ferring Pharmaceuticals, it is licensed in proprietary and generic forms for the delay of imminent preterm birth in pregnant adult women.
The most commonly reported side effect is nausea.[4]
Tractocile EPAR
was invoked but never defined (see the help page).